ArticleBreast cancer research and treatment2026
Extracellular vesicles in nipple discharge for breast cancer screening.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNipple discharge (ND) is one of its major symptoms of breast cancer. However, the low volume of NDs has limited their diagnostic capability. This study aimed to identify extracellular vesicles (EVs) miRNAs in ND using cellulose nanofiber (CNF) sheets to develop clinical biomarkers.
methodsPatients with ND from two independent institutions between 2023 and 2024 were included. ND-EVs were isolated from 23 samples [normal, n = 8; intraductal papilloma, n = 1; ductal carcinoma in situ (DCIS), n = 8; invasive ductal carcinoma, n = 6] using CNF sheets. Additionally, miRNAs were also analyzed from intracystic fluid, tumor tissue, and tissue surface EVs from the same patients, and miRNA sequencing was performed.
resultsmiRNA sequencing for ND-EVs revealed distinct clustering between cancer and normal groups, identifying miR-342-3p, miR-20b-5p, and miR-550a-5p as candidate biomarkers. ND-EV miRNA profiles reflected tumor tissue characteristics, especially in DCIS. Four additional miRNAs (miR-92b-3p, miR-375-3p, miR-182-5p, miR-96-5p) were commonly upregulated in DCIS tissue, tissue surface, and ND-EVs. These miRNAs were validated by qRT-PCR. ROC curve analyses demonstrated that combining the five miRNAs yielded high diagnostic performance, with AUCs of 0.902 for breast cancer and 0.938 for DCIS. A subset of three miRNAs also showed robust discrimination ability.
conclusionND-EV miRNAs collected via CNF sheets show great potential as noninvasive biomarkers for early breast cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.